Mauro Garcia-Altieri,Keila Carrera-Mejias,Ruben Hernaez
Mauro Garcia-Altieri
Fecal microbiota transplant in liver diseases: Current evidence and future directions [0.03%]
粪菌移植在肝脏疾病中的应用：现有证据与未来方向
Rahul Karna,Michael Babich
Rahul Karna
Mzamo Mbelle,Geoffrey Dusheiko
Mzamo Mbelle
1_a435pedtKaltura. Copyright © 2024 American Association for the Study of Liver Diseases.
Improving access to screening and treatment of hepatocellular carcinoma in the United States [0.03%]
改善美国肝细胞癌筛查和治疗的获取途径
Jessica P E Davis,Atoosa Rabiee
Jessica P E Davis
Untangling frailty, sarcopenia, and physical fitness in cirrhosis [0.03%]
肝硬化患者衰弱、肌少症和体能的相互关系及其影响因素探讨
Andres Duarte-Rojo,Rehaan Bux,James Sliwa
Andres Duarte-Rojo
Tiffany Wu,Jeremy Louissaint
Tiffany Wu
Immune-mediated liver injury from checkpoint inhibitors: Best practices in 2024 [0.03%]
2024年检查点抑制剂引起的免疫介导性肝损伤的最佳实践
Linnea A Swanson,Fadi Hawa,Robert J Fontana
Linnea A Swanson
Gordon S Hill,Shawn M Cohen,Melissa B Weimer
Gordon S Hill
Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease [0.03%]
与代谢紊乱相关脂肪肝病和心血管疾病
Tooba Laeeq,Kyaw Min Tun
Tooba Laeeq